TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shionogi & Co ( (JP:4507) ) has provided an announcement.
Shionogi & Co. reported its consolidated financial results for the first quarter of fiscal year 2025, showing a revenue increase of 2.2% compared to the previous year. The company also experienced significant growth in operating profit and profit before tax, indicating strong financial performance. The company’s financial forecast for the year ending March 2026 anticipates continued revenue and profit growth, reflecting positive market positioning and operational efficiency.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company listed on the Tokyo Stock Exchange, primarily focused on the research, development, and marketing of pharmaceutical products. The company is known for its contributions to the healthcare industry, particularly in the development of treatments for infectious diseases.
YTD Price Performance: 16.54%
Average Trading Volume: 2,478,430
Technical Sentiment Signal: Buy
Current Market Cap: Yen2246.3B
For an in-depth examination of 4507 stock, go to TipRanks’ Overview page.